Antimicrobial susceptibility of pathogens isolated from surgical site infections in Japan: Comparison of data from nationwide surveillance studies conducted in 2010 and 2014–2015Yoshio Takesue, Katsunori Yanagihara, Shinya Kusachi et al.|Journal of Infection and Chemotherapy|2017Cited by 51
Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trialJunichi Koike, Shingo Kameoka, Hirotoshi Hasegawa et al.|Cancer Chemotherapy and Pharmacology|2017Cited by 50
Antimicrobial susceptibility of common pathogens isolated from postoperative intra-abdominal infections in JapanYoshio Takesue, Katsunori Yanagihara, Shinya Kusachi et al.|Journal of Infection and Chemotherapy|2018Cited by 37
Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancerYoshinori Munemoto, Hideyuki Mishima, Mitsuro Kanda et al.|BMC Cancer|2015Cited by 18
Corrigendum to “Antimicrobial susceptibility of common pathogens isolated from postoperative intra-abdominal infections in Japan” [J Infect Chemother 24 (2018) 330–340]Yoshio Takesue, Katsunori Yanagihara, Shinya Kusachi et al.|Journal of Infection and Chemotherapy|2018Cited by 3